JP2019511570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511570A5 JP2019511570A5 JP2018565253A JP2018565253A JP2019511570A5 JP 2019511570 A5 JP2019511570 A5 JP 2019511570A5 JP 2018565253 A JP2018565253 A JP 2018565253A JP 2018565253 A JP2018565253 A JP 2018565253A JP 2019511570 A5 JP2019511570 A5 JP 2019511570A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- aav
- ventricle
- progranulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030769A JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302525P | 2016-03-02 | 2016-03-02 | |
| US62/302,525 | 2016-03-02 | ||
| PCT/US2017/020397 WO2017151884A1 (en) | 2016-03-02 | 2017-03-02 | Therapy for frontotemporal dementia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022030769A Division JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511570A JP2019511570A (ja) | 2019-04-25 |
| JP2019511570A5 true JP2019511570A5 (https=) | 2020-03-19 |
| JP7436089B2 JP7436089B2 (ja) | 2024-02-21 |
Family
ID=59743281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565253A Active JP7436089B2 (ja) | 2016-03-02 | 2017-03-02 | 前頭側頭型認知症の治療 |
| JP2022030769A Active JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022030769A Active JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190328906A1 (https=) |
| EP (1) | EP3423109A4 (https=) |
| JP (2) | JP7436089B2 (https=) |
| AU (1) | AU2017227803B2 (https=) |
| CA (1) | CA3016314A1 (https=) |
| WO (1) | WO2017151884A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US20190328906A1 (en) * | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| US20240002459A1 (en) * | 2016-07-14 | 2024-01-04 | Emory University | Granulin Compositions and Uses Related Thereto |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| AU2018346104B2 (en) | 2017-10-03 | 2023-07-27 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| BR112020008033A2 (pt) * | 2017-10-23 | 2020-10-27 | Prevail Therapeutics, Inc. | terapias gênicas para doença neurodegenerativa |
| EP3717505A4 (en) | 2017-12-01 | 2021-12-01 | Encoded Therapeutics, Inc. | GENENICALLY MODIFIED DNA-BINDING PROTEINS |
| KR20210019996A (ko) | 2018-05-15 | 2021-02-23 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 조성물 및 방법 |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP7624919B2 (ja) * | 2018-10-16 | 2025-01-31 | デナリ セラピューティクス インコーポレイテッド | プログラニュリン関連障害を処置及びモニタリングするための方法 |
| WO2020160458A1 (en) | 2019-02-01 | 2020-08-06 | Avrobio, Inc. | Compositions and methods for treating neurocognitive disorders |
| BR112021015817A2 (pt) * | 2019-02-22 | 2021-10-13 | The Trustees Of The University Of Pennsylvania | Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| CA3136004A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| PL3976798T3 (pl) | 2019-05-29 | 2026-04-07 | Encoded Therapeutics, Inc. | Kompozycje i sposoby selektywnej regulacji genów |
| GB201913974D0 (en) * | 2019-09-27 | 2019-11-13 | King S College London | Vector |
| MX2022004812A (es) * | 2019-10-22 | 2023-02-23 | Applied Genetic Tech Corporation | Sistemas de virus adeno-asociados (aav) para el tratamiento de enfermedades o trastornos neurodegenerativos asociados a la progranulina. |
| EP4146797A1 (en) * | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| US20230227847A1 (en) * | 2020-05-27 | 2023-07-20 | Universität Zürich | Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia |
| AU2021325891A1 (en) * | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
| BR112023002374A2 (pt) * | 2020-08-12 | 2023-03-21 | UCB Biopharma SRL | Terapia genética usando construções de ácido nucléico compreendendo sequências promotoras de proteína 2 de ligação de metil cpg (mecp2) |
| EP4204014A1 (en) * | 2020-08-26 | 2023-07-05 | The Trustees of The University of Pennsylvania | Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2024035649A1 (en) * | 2022-08-08 | 2024-02-15 | Shape Therapeutics Inc. | Compositions for progranulin expression and methods of use thereof |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE031156T2 (en) * | 2006-06-07 | 2017-06-28 | Genzyme Corp | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| WO2009089635A1 (en) * | 2008-01-16 | 2009-07-23 | Neurodyn, Inc. | Treating neurodegenerative diseases with progranulin (pgrn) |
| HRP20250897T1 (hr) * | 2009-05-02 | 2025-09-26 | Genzyme Corporation | Genska terapija za neurodegenerativne poremećaje |
| US20110203007A1 (en) * | 2010-02-16 | 2011-08-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis |
| US20190328906A1 (en) | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
-
2017
- 2017-03-02 US US16/081,346 patent/US20190328906A1/en active Pending
- 2017-03-02 WO PCT/US2017/020397 patent/WO2017151884A1/en not_active Ceased
- 2017-03-02 JP JP2018565253A patent/JP7436089B2/ja active Active
- 2017-03-02 AU AU2017227803A patent/AU2017227803B2/en active Active
- 2017-03-02 EP EP17760789.2A patent/EP3423109A4/en active Pending
- 2017-03-02 CA CA3016314A patent/CA3016314A1/en active Pending
-
2022
- 2022-03-01 JP JP2022030769A patent/JP7507808B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511570A5 (https=) | ||
| JP2020528734A5 (https=) | ||
| JP2020519629A5 (https=) | ||
| JP2018508519A5 (https=) | ||
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| JP2016503405A5 (https=) | ||
| JP2020513811A5 (https=) | ||
| TW201840850A (zh) | 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症 | |
| JP2021512072A5 (https=) | ||
| JP2019513779A5 (https=) | ||
| JP2017529395A5 (https=) | ||
| JP2009526067A5 (https=) | ||
| JP2019537576A5 (https=) | ||
| JP2017518271A5 (https=) | ||
| JP2021500352A5 (https=) | ||
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| CA3025445A1 (en) | Dual overlapping adeno-associated viral vector system for expressing abc4a | |
| JP2020509786A5 (https=) | ||
| JP2023537980A5 (https=) | ||
| JP2023537358A5 (https=) | ||
| JP2021520811A5 (https=) | ||
| JP2023065516A5 (https=) | ||
| JP2023515795A5 (https=) | ||
| JP2021511020A5 (https=) | ||
| IL319564A (en) | BAG 3 methods and uses for treating cardiac amyloidosis |